|
Post by Sam on Mar 15, 2016 1:15:15 GMT
HAIFA, Israel, February 22, 2016 /PRNewswire/ --
Lipogen Ltd. attained a US patent for its proprietary phospholipid formulation designed to tackle Premenstrual Syndrome (PMS) and premenstrual dysphoric disorder (PMDD). These sometimes debilitating conditions occur in some 15% of pre-menopausal women aged 25-44. The patent was approved for "compositions and methods for alleviating symptoms associated with premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD)."
|
|